Ruthenium complexes: - Potential candidate for anti-tumour activity

International Journal of ChemTech Research

Volumn 6, Issue 1, 2014, Pages 828-837

  Sharma, A R ^a   Gangrade, D M ^a   Bakshi, S D ^a   John, J S ^a  

^a Vivekanand Education Society's College of Pharmacy   (India)

Author keywords

Cancer; Innovative therapies; Ruthenium complex; Transition metal

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CISPLATIN; FLUOROURACIL; KP1019; KP1339; RUTHENIUM COMPLEX; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL (TOPIC); HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; NAUSEA AND VOMITING; NEOPLASM; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OXIDATION REDUCTION POTENTIAL; ULTRAVIOLET SPECTROSCOPY; X RAY CRYSTALLOGRAPHY;

EID: 84893492502     PISSN: 09744290     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. National Cancer Institute, www.cancer.gov.
2. Fesser K., Bednarski P., and Saczewski F.: "Synthesis, characterization, anti-tumor and antimicrobial activities of heterocyclic transition metal complexes", Thesis, university of Griswold, 2011.
3. DeVita V.T.; Chu Jr. E. A History of Cancer Chemotherapy. Cancer Res. 2008, 68: 21, 8643-8653.
4. M.J. Piccart, H. Lamb, J.B.Vermorken: Current and future potential roles of the platinum drugs in the treatment of ovarian cancer, Annals of Oncology 2001, 12, 1195-1203.
5. Tarchiani G.; Vitale S. Inorganic arsenic in therapy with particular attention to antileukemic therapy. Clin. Ter. 1964, 31, 101-116.
6. Andrews P, Howell S, Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance. Cancer Cells, 1990, 2:35-43.
7. Rosenberg B. Platinum complexes for the treatment of cancer: why does the search go on. In: Lippert B.: Cisplatin. Chemistry and Biochemistry of a leading Anticancer Drug. Zurich, Switzerland. Verlag Helvetica Chimica Acta, Postfach CH-8042 Zurich, Switzerland, 1999, 3-27.
8. T. Boulikas, M. Vougiouka, Cisplatin and platinum drugs at the molecular level (Review), Oncol. Rep. 2003, 10, 1663-1682.
9. E. Wong, C.M. Giandomenico, current status of platinum based antitumor drugs Chem. Rev. 1999, 99, 2451-2466.
10. M. Galanski, V.B. Arion, M.A. Jakupec, B.K. Keppler, Recent developments in the field of tumor-inhibiting metal complexes Curr. Pharm. Des 2003, 9, 2078-2089.
11. M.A. Fuertes, C. Alonso, J.M. Perez, Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance, Chem. Rev. 2003, 103, 645-662.
12. R. Agarwal, S.B. Kaye, Ovarian cancer: strategies for overcoming resistance to chemotherapy, Nat. Rev. Cancer 2003, 3, 502-516.
13. A. Sigel, H. Sigel (Eds.), Metal Ions in Biological Systems, Metal Ions and Their Complexes in Medication, Marcel Dekker, New York, 2004, 41.
14. A. Sigel, H. Sigel (Eds.), Metal Ions in Biological Systems, Metal Complexes in Tumor Diagnosis and as Anticancer Agents, Marcel Dekker, New York, 2004, 42.
15. M. A. Jakupec, M. Galanski, V. B. Arion, C. G. Hartinger, B. K. Keppler, Anti tumor metal compounds: More than theme and variations, Dalton Trans. 2008, 183, 194.
16. P. C. A. Bruijnincx, P. Sadler, New trends for metal complexes with anticancer activity, J. Curr. Opin. Chem. Biol. 2008, 12, 197-206.
17. L. Ronconi, P.Sadler, J.Coord, Using coordination chemistry to design new medicines, Chem. Rev. 2007, 251, 1633-1648.
18. P. J. Dyson, G. Sava, Metal-based anti-tumour drugs in the post genomic era, Dalton Trans. 2006, 1929, 1933.
19. C.S. Allardyce, A.Dorcier, C.Scolaro, P.J.Dyson, Development of organmetallic (organo-transition metal) pharmaceuticals, Appl. Organomet. Chem. 2005, 19, 1-10.
20. R. Paschke, C. Paetz, T. Mueller, H.-J. Schmoll, H. Mueller, E. Sorkau, E. Sinn, Biomolecules linked to transition metal complexes--new chances for chemotherapy, Curr. Med. Chem. 2003, 10, 2033-2044.
21. C.X. Zhang, S.J. Lippard, New metal complexes as potential therapeutics, Curr. Opin. Chem. Biol. 2003, 7, 481-489.
22. J. Reedijk, New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA, Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 3611-3616.
23. M. J. McKeage, L. Maharaj, S. J. Berners-Price, Mechanisms of cytotoxicity and antitumor activity of gold (I) phosphine complexes: the possible role of mitochondria Coord. Chem. Rev. 2002, 232, 127-135.
24. R.A. Sanchez-Delgado, A. Anzellotti, Metal complexes as chemotherapeutic agents against tropical diseases: trypanosomiasis, malaria and Leishmaniasis, Mini rev. Med. Chem. 2004, 4, 23-30.
25. Kostova I., Ruthenium complexes as anti cancer agents Curr. Med. Chem. 2006,13, 1085-1107.
26. G. Sava, A. Bergamo, Ruthenium-based compounds and tumour growth control, Int. J. Oncol. 2000, 17, 353-365.
27. Jung Y.; Lippard S. J. direct cellular responses to platinum-induced DNA damage. Chem. Rev. 2007, 107, 1387-1407.
28. Hambley T.W. Developing new metal-based therapeutics: challenges and opportunities. Dalton Trans. 2007, 43, 4929-4937.
29. Keppler B. K., Berger M. R., Klenner T. H., Heim M. E.; Metal complexes as antitumor agents. Adv. Drug. Res. 1990, 19, 243.
30. Avendano C.; Menendez J.C. Medicinal Chemistry of Anticancer Drugs, Chapter 8: Anticancer Drugs Targeting Tubulin and Microtubules, Elsevier B.V. 2008, 1, 229-249.
31. E. Wong, C. M. Giandomenico, Current status of platinum-based antitumor drugs, Chem. Rev. 1999, 99, 2451-2466
32. Dyson P. J., Sava G. Metal-based antitumour drugs in the post genomic era. Dalton Trans. 2006, 1929-1933.
33. Jakupec M. A.; Galanski M.; Arion V. B.; Hartinger C. G.; Keppler B. K. Antitumour metal compounds: More than theme and variations. Dalton Trans. 2008, 183-194.
34. Schluga P.; Hartinger C.G.; Egger A.; Reisner E.; Galanski M.; Jakupec M.A.; Keppler B.K. Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans. 2006, 1796-1802.
35. Clarke M.J. Ruthenium metallopharmaceuticals. Coord. Chem. Rev. 2002, 232, 69-93.
36. G. Sava, E. Alessio, A. Bergamo, G. Mestroni, in: M.J. Clarke, P.J. Sadler (Eds.), Topics in Biological Inorganic Chemistry, 1999, 1, 143-169.
37. B.K. Keppler, M. Henn, U.M. Juhl, M.R. Berger, R. Niebl, F.E. Wagner, New ruthenium complexes for the treatment of cancer. Prog. Clin. Biochem. Med. 1989, 10, 41-69.
38. Mitra A.; Lay P.A. Recent developments in ruthenium anticancer drugs. Metallomics. 2009, 1, 458-470.
39. Ang W.H.; Dyson P.J. Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy. Eur. J. Inorg. Chem. 2006, 4003-4018.
40. David S., Perkins R. S. Fronczek F. R., Synthesis, characterization, and anticancer activity of ruthenium-pyrazole complexes, J. Inorg. Biochem. 2012, 111, 33-39.
41. K.G. Lipponer, E. Vogel, B.K. Keppler, Synthesis, Characterization and Solution Chemistry of trans-Indazoliumtetrachlorobis(Indazole)ruthenate (III), A New Anti-Cancer Ruthenium complex. IR, UV, NMR, HPLC Investigations and Anti-tumor activity. Crystal Structures of trans-1-methylindazoliumtetrachlorobis-(1-methylindazole) ruthenate(III) and its Hydrolysis product trans-Monoaquatrichlorobis-(1-methylindazole)-ruthenate(III), Metal Based Drugs 1996, 3, 243-260.
42. A. Kueng, T. Pieper, R. Wissiack, E. Rosenberg, B.K. Keppler, Hydrolysis of the tumor-inhibiting ruthenium(III) complexes HIm trans-[RuCl4(im)2] and HInd trans-[RuCl4(ind)2] investigated by means of HPCE and HPLC-MS, J. Biol. Inorg. Chem. 2001, 6, 292-299.
43. M. Pongratz, P. Schluga, M.A. Jakupec, V.B. Arion, Ch.G. Hartinger, G. Allmaier, B.K. Keppler, Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy, J. Anal. At. Spectrom. 2004, 19, 46-51.
44. Pluim D.; Van Waardenburg R.C.A.M.; Beijnen J.H.; Schellens J.H.M. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines Cancer Chemother. Pharmacol. 2004, 54, 71-78.
45. Kulkarni N.V.; Hegde G.S.; Kurdekar G.S.; Budagumpi S.; Sathisha M.P.; Revankar V.K. Spectroscopy, Electrochemistry, and Structure of 3d-Transition Metal Complexes of Thiosemi carbazones with Quinoline Core: Evaluation of Antimicrobial Property. Spectrosc. Lett. 2010, 43, 235-246.
46. Parmar S.; Kumar Y. Synthesis, Spectroscopic, and Antimicrobial Studies of the Bivalent Nickel, and Copper Complexes of Thiosemicarbazide. Chem. Pharm. Bull. 2009,57, 603-606.
47. Rodriguez-Arguelles M.C.; Lopez-Silva E.C.; Sanmartin J.; Pelagatti P.; Zani F. Copper complexes of imidazole-2-, pyrrole-2-and indol-3-carbaldehyde thiosemicarbazones: Inhibitory activity against fungi and bacteria. J. Inorg. Biochem. 2005, 99, 2231-2239.
48. Patole J.; Sandbhor U.; Subhash P.; Deobagkar D.N.; Anson C.E.; Powell A. Structural chemistry and in vitro antitubercular activity of acetylpyridine benzoyl hydrazone and its copper complex against Mycobacterium smegmatis. Bioorg. Med. Chem. Lett. 2003, 13, 51-55.